Overview

This forum examines multiple modifiable coronary heart disease (CHD) risk factors and evidence-based data supporting CHD risk reduction through modification of these risk factors. Specifically, it provides the latest evidence on metabolic and cardiovascular risk factors; relates evidence-based clinical data that demonstrate the importance of aggressive LDL reduction, especially in high-risk patients; and discusses the impact and importance of various therapies to reduce CHD risk.

moderator
Daniel J. Rader, MD Cooper-McClure Professor of Medicine Pathology, and Pharmacology Director, Preventive Cardiovascular Medicine and Lipid Clinic Director, General Clinical Research Center Associate Director Institute for Translational Medicine and Therapeutics University of Pennsylvania School of Medicine Philadelphia, PA
speakers
Roger S. Blumenthal, MD, FACC, FCCP, FAHA Associate Professor of Medicine Division of Cardiology Director, Preventive Cardiology Johns Hopkins Hospital Baltimore, MD		Lori J. Mosca, MD, MPh, PhD Associate Professor of Medicine Columbia University College of Physicians and Surgeons Director, Preventive Cardiology New York-Presbyterian Hospital Director, Columbia Center for Heart Disease Prevention New York, NY
Allan D. Sniderman, MD Edwards Professor of Cardiology Professor of Medicine McGill University Director, Mike Rosenbloom Laboratory for Cardiovascular Research Royal Victoria Hospital Montreal, Quebec	Christopher P. Cannon, MD Associate Professor of Medicine Harvard Medical School Associate Physician, Cardiovascular Division Brigham and Women's Hospital Boston, MA

SPONSORED BY	SUPPORTED THROUGH AN EDUCATIONAL GRANT FROM	ENDORSED BY	EDUCATIONAL PARTNER